RELX Outlines at the GTNF Role of Technology in Advancing Vaping Industry’s Responsible Practices
21.9.2020 15:29:00 EEST | Business Wire | Press release
The company’s Global External Affairs Lead provided concrete examples of how RELX has been harnessing the power of technology, innovation and research in its quest to forge ahead robust youth prevention mechanisms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005456/en/
Jonathan Ng speaking at the GTNF Innovations on the Horizon panel. (Photo: Business Wire)
At the virtual Global Tobacco & Nicotine Forum (GTNF) event yesterday, RELX Technology’s Global Head of External Affairs Jonathan Ng spoke on a panel entitled “Innovations on the Horizon.” The panel explored several topics related to the growing international acceptance of e-cigarettes as better alternatives to cigarettes, innovations related to user experience and youth prevention, and illicit trade. GTNF is one of the leading tobacco and nicotine forums in the world; speakers and attendees include public health experts, government representatives, investors and members of the tobacco and nicotine industries.
This year’s GTNF focused on how the industry can achieve sustainable change through innovation and regulation by responding to the growing demand from consumers for new products and the constant challenges from our global society to be responsible and accountable corporate citizens.
In that spirit, Mr. Ng explained that, “Beyond innovations to the product to enhance adult users’ experiences, there are many areas where science, research and technology can complement the products. And these are very important for an industry like ours, as we look to uphold our commitment to responsible business practices and behaviour.”
Mr. Ng detailed the lengths RELX has gone to in ensuring minors are not attracted to, and are prevented from, using their products. RELX has developed innovative products that are equipped with cutting-edge technologies that prevent minors from accessing e-cigarette products. In 2019, RELX launched the RELX i, which features a remote locking function that allows the user to lock the device by a simple tap on the app to prevent unauthorized use.
In addition, Mr. Ng stated that in China, RELX launched the Sunflower System, a first-of-its-kind minor prevention system for all RELX stores. RELX store customers need to verify their age through a facial recognition process that matches the customer’s face to the photo on their Resident ID card, to ensure the customer is of legal age to purchase e-cigarette products.
To address concerns that fruit or dessert names might be particularly attractive to youth, RELX has even taken the industry-leading decision to give its products neutral names like Fresh Red and Mellow Yellow.
In the same vein, Mr Ng announced that RELX is also developing a tracking system that connects customers, product bar codes and shop locations that will allow for the company to trace a product to its point of sale if a minor is found to be in possession of a RELX product.
About the Global Tobacco & Nicotine Forum
The Global Tobacco & Nicotine Forum (GTNF) exists thanks to the vision and direction of its founder and president, Elise Rasmussen. In January 2019, Elise became the executive director of the GTNF Trust, part of a new division under the auspices of the Tobacco Merchants Association (TMA). From its launch in Rio de Janeiro in 2008 to the present day, the GTNF has become the global exchange for views and ideas among public health experts, government representatives, investors and members of the tobacco/nicotine industries.
ABOUT RELX Technology
Founded in January 2018, RELX is Asia’s leading e-cigarette brand. RELX independently develops its e-cigarette products at its R&D center in Shenzhen, China. RELX’s mission is to empower adult smokers through technology, product and science, ethically. RELX continues to make significant investments in R&D, e-liquid testing and new product development. Just recently, RELX announced the start of its operations at its newly-established bioscience laboratory to conduct systematic research on the effects of e-cigarettes through in vivo and in vitro tests, as well as conduct pre-clinical safety assessments. The company has attracted global talents from Uber, Proctor and Gamble, Huawei, Beats, and L’Oréal. RELX investors include top venture capital firms Source Code Capital, IDG Capital, and Sequoia Capital.
Website: https://relxnow.com
Twitter: @Relxtech
Facebook: @Relxnow
Instagram: relxtech
Linkedin: RELX Technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200921005456/en/
Contact information
Yasha Wolfman
yasha.wolfman@relxtech.com
Aimee Ren
aimee.ren@relxtech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 13:00:00 EET | Press release
Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe
SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 12:40:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss on intangible assets to income from operations was
NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 12:00:00 EET | Press release
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding to 30 by the end of 2026 Introduction of NIQ’s exclusive EQ2 metric, multiplying units by number in pack to reflect true consumption “The pace of
European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 09:47:00 EET | Press release
European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
